Immuron CEO, Steven Lydeamore Investor Webinar Presentation
Immuron Limited (ASX: IMC; NASDAQ: IMRN) announced that their CEO, Steven Lydeamore, will be presenting at the Monsoon Communications Investor function in Sydney, Australia. The presentation slide deck is available on the company's website for public access.
02/08/2024 - 06:00 AM
MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at the Monsoon Communications Investor function on Thursday, 8th February in Sydney, Australia.
A copy of the presentation slide deck is available on the Company’s website.
https://www.immuron.com.au/corporate-presentations/
Authorized for release by the Board of Immuron Limited.
COMPANY CONTACT: Steven Lydeamore Chief Executive Officer info@immuron.com
About Immuron
For more information visit: http://www.immuron.com
When and where will Steven Lydeamore be presenting?
Steven Lydeamore will be presenting at the Monsoon Communications Investor function on Thursday, 8th February in Sydney, Australia.
Where can I find the presentation slide deck?
The presentation slide deck is available on Immuron Limited's website at https://www.immuron.com.au/corporate-presentations/
What are the contact details for Immuron Limited?
You can contact Immuron Limited via email at info@immuron.com or by phone at +61 (0)3 9824 5254
IMRN Rankings
#3053 Ranked by Stock Gains
IMRN Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Pharmaceuticals: Major, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
Australia
City
Melbourne
About IMRN
immuron ltd is a publicly listed australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system and gut microbiome. immuron’s technology platform is capable of developing and producing an orally stable therapeutic as a potential ‘oral targeted therapy’ for various immune mediated and inflammatory disorders, among them: non-alcoholic steatohepatitis (nash) diabetes, colitis, arthritis, inflammatory bowel diseases (ibd), irritable bowel syndrome (ibs), liver fibrosis and other chronic disorders in which the immune system plays a key role in thier pathogenesis. these disorders represent areas of growing and unmet medical need, where oral targeted therapy drugs could offer significant advantages due to the lack of absorption and the high safety profile. immuron has one marketed product, which provides proof of concept for its oral immune technology platform, and a pipeline of products at various stages of cl
